JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
The evaluation of presepsin level and bacterial infection in neutropenic patients
Abstract
Aims: Neutropenia is a life-threatening condition that is seen as a complication of chemotherapy, especially in cancer patients, if the patient is infected. Early treatment of the infection has aimportant effect on mortality. Our aim in this study is to investigate the usability of presepsin in terms of diagnosis of bacterial infection in patients who are neutropenic after chemotherapy.
Methods: In this study, presepsin, erythrocyte sedimentation rate (ESR), CRP (C-reactive protein), and procalcitonin were measured in 25 neutropenic patients, and a comparison was made between those who were culture positive and negative, those who had a fever and those who did not. In addition, presepsin and CRP values were compared with the control group of 22 people.
Results: Presepsin, CRP, ESR and procalcitonin were significantly higher in those who did not reproduce in each culture (p<0.001, p=0.003, p=0.026, p<0.01, respectively) compared to those who did not have a fever (p<0.001, p<0.001, p < 0.001, p=0.019, respectively).
Conclusion: Presepsin has the potential to be used in the early evaluation of bacterial infection in neutropenic patients. However, more work should be done on this issue.

Keywords : Presepsin, neutropenic fever, C-reactive protein, procalcitonin, cancer

Download Article


1. Frei E, 3rd. Curative cancer chemotherapy. Cancer Res. 1985; 45(12 Pt1): 6523-37.
2. Furue H. Chemotherapy cancer treatment during the past sixty years.Gan to Kagaku Ryoho Cancer Chemother. 2003; 30: 1404-1411.
3. Fontanella C, Bolzonello S, Lederer B, Aprile G. Management ofbreast cancer patients with chemotherapy-induced neutropeniaor febrile neutropenia. Breast Care (Basel). 2014;9(4):239-245.doi:10.1159/000366466
4. Lalami Y, Klastersky J. Impact of chemotherapy-induced neutropenia(CIN) and febrile neutropenia (FN) on cancer treatment outcomes:An overview about well-established and recently emerging clinicaldata. Crit Rev Oncol Hematol. 2017;120:163-179. doi:10.1016/j.critrevonc.2017.11.005
5. Yaegashi Y, Shirakawa K, Sato N, et al. Evaluation of a newly identifiedsoluble CD14 subtype as a marker for sepsis. J Infect Chemother.2005;11(5):234-238. doi:10.1007/s10156-005-0400-4
6. Memar MY, Baghi HB. Presepsin: A promising biomarker for thedetection of bacterial infections. Biomed Pharmacother. 2019;111:649-656. doi:10.1016/j.biopha.2018.12.124
7. Malko&ccedil; M, Kural B. Presepsin: Sepsis tespiti i&ccedil;in umut verici yeni birbiyobelirte&ccedil;. Celal Bayar &Uuml;niversitesi Sağlık Bilimleri Enstit&uuml;s&uuml; Dergisi.2021; 8(3): 553-557. doi: 10.34087/cbusbed.887818
8. Lippi G. Sepsis biomarkers: past, present and future. Clin Chem LabMed. 2019;57(9):1281-1283. doi:10.1515/cclm-2018-1347
9. Marcıo Borges SA, Crespo RZ. Screening and early detection of sepsis.The Sepsis Codex-E-Book, 2023: 41.
10. Yılmaz R. Monit&ouml;rizasyonda biyobelirte&ccedil;ler. Boşnak M, edit&ouml;r. &Ccedil;ocukyoğun bakımda monit&ouml;rizasyon. 1. Baskı. Ankara: T&uuml;rkiye Klinikleri;2022. p.98-114.
11. Okamura Y, Yokoi H. Development of a point-of-care assay system formeasurement of presepsin (sCD14-ST). Clinica Chimica Acta; Int J ClinChemistry. 2011; 412: 2157-2161.
12. &Ouml;zdemir ZC, D&uuml;zenli-Kar Y, Canik A, K&uuml;sk&uuml;-Kiraz Z, &Ouml;zen H, B&ouml;r&Ouml;. The predictive value of procalcitonin, C-reactive protein, presepsin,and soluble-triggering receptor expressed on myeloid cell levels inbloodstream infections in pediatric patients with febrile neutropenia.Turk J Pediatr. 2019;61(3):359-367. doi:10.24953/turkjped.2019.03.007
13. Olad E, Sedighi I, Mehrvar A, et al. Presepsin (scd14) as a markerof serious bacterial infections in chemotherapy induced severeneutropenia. Iran J Pediatr. 2014;24(6):715-722.
14. Maurice M, Nafea D, Sawy M, Swelem R, Youssef S. Usefulness ofpresepsin (soluble CD14 subtype) as a diagnostic marker of sepsis inEgyptian patients with acute myeloid leukemia. Am J Mol Biol 2014; 4:169-176.
15. Bamba Y, Moro H, Aoki N, et al. Increased presepsin levels areassociated with the severity of fungal bloodstream infections. PLoSOne. 2018;13(10):e0206089. doi:10.1371/journal.pone.0206089
16. Koizumi Y, Shimizu K, Shigeta M, et al. Plasma presepsin level is anearly diagnostic marker of severe febrile neutropenia in hematologicmalignancy patients. BMC Infect Dis. 2017;17(1):27. doi:10.1186/s12879-016-2116-8
17. Jereb M, Mavric M, Skvarc M, et al. Usefulness of presepsin asdiagnostic and prognostic marker of sepsis in daily clinical practice. JInfect Dev Ctries. 2019;13(11):1038-1044. doi:10.3855/jidc.11764
18. Mihajlovic D, Brkic S, Uvelin A, Draskovic B, Vrsajkov V. Use ofpresepsin and procalcitonin for prediction of SeptiFast results incritically ill patients. J Crit Care. 2017;40:197-201. doi:10.1016/j.jcrc.2017.04.008
19. Guarino M, Perna B, Maritati M, et al. Presepsin levels and COVID-19severity: a systematic review and meta-analysis [published online aheadof print, 2022 Nov 15]. Clin Exp Med. 2022;1-10. doi:10.1007/s10238-022-00936-8
20. Kim SW, Lee H, Lee SH, Jo SJ, Lee J, Lim J. Usefulness of monocytedistribution width and presepsin for early assessment of disease severityin COVID-19 patients. Medicine (Baltimore). 2022;101(27):e29592.doi:10.1097/MD.0000000000029592
Article available in :
Volume 1, Issue 1, 2023
Page : 5-8
https://doi.org/10.51271/JCHOR-0002
Article Information
Received : 24 Oca 2023
Accepted : 24 Şub 2023
Published : 26 Şub 2023
Corresponding Author :

Merve Genç: Kırıkkale University, Faculty of Medicine, Department of Internal Medicine, Kırıkkale, Turkey

[email protected]
Citation : Genç M, Yalçın S, Kısa Ü. The evaluation of presepsin level and bacterial infection in neutropenic patients. JCHOR. 2023;1(1):.

Read: 249
Cited: 0
Download : 250
_Footer